Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera

Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Study ID
NCT06516406
Status
Recruiting
Apply to this trial

Conditions

  • Myelofibrosis
  • Primary Myelofibrosis
  • Secondary Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The study is observational multicenter retrospective and prospective cohort study of patients with primary or secondary myelofibrosis who have initiated therapy with ruxolitinib, prescribed as part of the normal course of care and completely independent of study participation. The primary purpose is to determine the impact of clinical and laboratory characteristics of myelofibrosis on the prognosis of patients treated with ruxolitinib, understood as long-term survival.

Key Dates

First listed
Jul 24, 2024
Start date
May 6, 2022
Status verified
Feb 2024
Primary completion
May 31, 2032
Completion
May 31, 2032

Study Design

Enrollment
1,055 participants (estimated)

Primary Outcome Measure

Long Term Survival [ Time Frame: 10 years ]

Central Contacts

Related Studies